June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Association between Genetic Polymorphisms of the Prostaglandin F2α Receptor Gene and Response to Latanoprost in Glaucoma and Ocular Hypertension Patients
Author Affiliations & Notes
  • Kazuhisa Sugiyama
    Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Mayumi Sakurai
    Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Tomomi Higashide
    Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Shinji Ohkubo
    Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Hisashi Takeda
    Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Yoshiaki Saito
    Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Footnotes
    Commercial Relationships Kazuhisa Sugiyama, None; Mayumi Sakurai, None; Tomomi Higashide, None; Shinji Ohkubo, Topcon (C), Nidek (C); Hisashi Takeda, None; Yoshiaki Saito, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 762. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kazuhisa Sugiyama, Mayumi Sakurai, Tomomi Higashide, Shinji Ohkubo, Hisashi Takeda, Yoshiaki Saito; Association between Genetic Polymorphisms of the Prostaglandin F2α Receptor Gene and Response to Latanoprost in Glaucoma and Ocular Hypertension Patients. Invest. Ophthalmol. Vis. Sci. 2013;54(15):762.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To examine whether intraocular pressure (IOP) reduction by latanoprost correlates with the single nucleotide polymorphism (SNP) of the prostaglandin F2α (FP) receptor gene in glaucoma and ocular hypertension (OH) patients.

Methods: We retrospectively examined clinical data of glaucoma and OH patients who were treated with latanoprost monotherapy in 1eye and who had at least two IOP measurements on different days at baseline and also when on the medication. In all patients, IOP reduction was evaluated by the percent IOP reduction (%ΔIOP), estimated by subtracting IOP fluctuations in the untreated fellow eye. Subjects were classified by %ΔIOP into 3 categories: 1) low responders (%ΔIOP <10%), 2) medium responders (%ΔIOP ≥10% and <25%), and 3) high responders (%ΔIOP ≥25%). Nine SNPs in FP receptor gene were examined. The correlation between the %ΔIOP and SNPs in the FP receptor gene was then analyzed.

Results: A total of 82 patients (42 males, 40 females) met the eligibility criteria and were included. The average IOP of the treated eyes was decreased from 16.7 ± 3.2 mmHg (mean ± SD) to 14.2 ± 2.5 mmHg by latanoprost (mean %ΔIOP: 15.3 ± 10.5%). Three SNPs, rs1073611, rs1073610, and rs12093097 were in strong linkage disequilibrium. The %ΔIOP of the CC homozygote in rs12093097 (14.1 ± 1.3 % (mean ± SE)) was significantly lower than that of the T carrier (20.2 ± 2.1%, P = 0.039). The allele or genotype distributions of 3 SNPs, rs1073611, rs1073610, and rs12093097, were found to be significantly associated with the category of IOP response to latanoprost. The results of multivariate logistic regression analysis demonstrated that the genotype of rs12093097 was the only significant factor which has an effect on the IOP response to latanoprost (medium + high responders vs. low responders: P = 0.032; odds ratio, 0.103; 95% confidence interval, 0.013-0.824; predictive value, 67.1%).

Conclusions: An association was found between rs12093097, rs1073611, and rs1073610 of the FP receptor gene and the response to latanoprost in patients with glaucoma and OH. These SNPs could affect the degree of IOP reduction by latanoprost.

Keywords: 503 drug toxicity/drug effects • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×